低危和中危甲状腺癌随访中数据驱动的甲状腺球蛋白截断值:ITCO真实世界分析
该前瞻性观察研究纳入意大利甲状腺癌观察站数据库中540例随访5年且抗Tg抗体阴性的分化型甲状腺癌患者,评估1年时血清甲状腺球蛋白对5年内结构性疾病的预测价值。基于无病个体Tg第97百分位建立数据驱动截断值:仅甲状腺切除术者为1.97 ng/mL,术后放射性碘残余消融者为0.84 ng/mL,高敏感度和阴性预测值支持其排除结构性疾病的潜力。
要点
- 仅甲状腺切除术者的数据驱动Tg截断值为1.97 ng/mL,阴性预测值98%。
- 术后放射性碘残余消融者的数据驱动Tg截断值为0.84 ng/mL。
- 排除26例结构性疾病患者后,有无放射性碘治疗者中位Tg无差异。
核心结论
- 该真实世界研究为1年血清Tg水平的持续可靠性提供了证据,所提出的数据驱动Tg截断值对全甲状腺切除伴或不伴放射性碘残余消融患者的临床决策有价值。
研究设计与样本
- 前瞻性观察研究,纳入意大利甲状腺癌观察站数据库贡献中心中540例随访5年且抗Tg抗体阴性的患者。
- 在1年随访时评估血清Tg水平,主要结局为随访5年内结构性疾病的检出。
- 分析前排除26例在任何时间点检出结构性疾病的患者。
主要发现
- 排除26例结构性疾病患者后,接受与未接受放射性碘治疗患者的中位Tg无差异。
- 基于无病个体Tg水平第97百分位建立数据驱动截断值:仅甲状腺切除术者为1.97 ng/mL,术后放射性碘残余消融者为0.84 ng/mL。
- 仅甲状腺切除术者的截断值低于Memorial Sloan Kettering癌症中心方案和ESMO指南所提出的值,但预测能力良好,阴性预测值为98%。
- 高敏感度和阴性预测值支持这些截断值在排除结构性疾病方面的潜力。
关键数值与推荐
- 仅甲状腺切除术者数据驱动Tg截断值为1.97 ng/mL,阴性预测值98%。
- 术后放射性碘残余消融者数据驱动Tg截断值为0.84 ng/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The utility of thyroglobulin (Tg) in the follow-up of patients with differentiated thyroid cancer has been well-documented. Although third-generation immunoassays have improved accuracy, limitations persist (interfering anti-Tg antibodies and measurement variability). Evolving treatment strategies require a reevaluation of Tg thresholds for optimal patient management. OBJECTIVE: To assess the performance of serum Tg testing in 2 populations: patients receiving total thyroidectomy and radioiodine remnant ablation (RRA) or treated with thyroidectomy alone. DESIGN: Prospective observational study. SETTING: Centers contributing to the Italian Thyroid Cancer Observatory database. PATIENTS: We included 540 patients with 5 years of follow-up and negative anti-Tg antibodies. INTERVENTIONS: Serum Tg levels assessed at 1-year follow-up visit. MAIN OUTCOME MEASURE: Detection of structural disease within 5 years of follow-up. RESULTS: After excluding 26 patients with structural disease detected at any time point, the median Tg did not differ between patients treated with or without radioiodine. Data-driven Tg thresholds were established based on the 97th percentile of Tg levels in disease-free individuals: 1.97 ng/mL for patients undergoing thyroidectomy alone (lower than proposed by the Memorial Sloan Kettering Cancer Center protocol and ESMO Guidelines, yet demonstrating good predictive ability, with a negative predictive value of 98% and 0.84 ng/mL for patients receiving postsurgical RRA. High sensitivity and negative predictive value supported the potential of these thresholds in excluding structural disease. CONCLUSION: This real-world study provides evidence for the continued reliability of 1-year serum Tg levels. The data-driven Tg thresholds proposed offer valuable insights for clinical decision-making in patients undergoing total thyroidectomy with or without RRA.
引用
- Grani G, D'Elia S, Puxeddu E, et al. Data-driven Thyroglobulin Cutoffs for Low- and Intermediate-risk Thyroid Cancer Follow-up: ITCO Real-world Analysis. J Clin Endocrinol Metab. 2025. PMID: 39150986. doi:10.1210/clinem/dgae559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。